全文获取类型
收费全文 | 2458篇 |
免费 | 98篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 24篇 |
妇产科学 | 22篇 |
基础医学 | 292篇 |
口腔科学 | 62篇 |
临床医学 | 209篇 |
内科学 | 639篇 |
皮肤病学 | 66篇 |
神经病学 | 176篇 |
特种医学 | 31篇 |
外科学 | 522篇 |
综合类 | 9篇 |
预防医学 | 92篇 |
眼科学 | 17篇 |
药学 | 156篇 |
肿瘤学 | 246篇 |
出版年
2022年 | 20篇 |
2021年 | 29篇 |
2020年 | 23篇 |
2019年 | 35篇 |
2018年 | 25篇 |
2017年 | 22篇 |
2016年 | 37篇 |
2015年 | 32篇 |
2014年 | 34篇 |
2013年 | 53篇 |
2012年 | 87篇 |
2011年 | 106篇 |
2010年 | 49篇 |
2009年 | 52篇 |
2008年 | 85篇 |
2007年 | 90篇 |
2006年 | 80篇 |
2005年 | 101篇 |
2004年 | 92篇 |
2003年 | 84篇 |
2002年 | 90篇 |
2001年 | 98篇 |
2000年 | 101篇 |
1999年 | 92篇 |
1998年 | 42篇 |
1997年 | 15篇 |
1996年 | 24篇 |
1995年 | 33篇 |
1994年 | 20篇 |
1993年 | 21篇 |
1992年 | 87篇 |
1991年 | 57篇 |
1990年 | 80篇 |
1989年 | 77篇 |
1988年 | 78篇 |
1987年 | 72篇 |
1986年 | 75篇 |
1985年 | 52篇 |
1984年 | 44篇 |
1983年 | 28篇 |
1980年 | 13篇 |
1979年 | 29篇 |
1978年 | 19篇 |
1976年 | 13篇 |
1975年 | 13篇 |
1974年 | 15篇 |
1970年 | 15篇 |
1968年 | 16篇 |
1967年 | 16篇 |
1965年 | 12篇 |
排序方式: 共有2572条查询结果,搜索用时 31 毫秒
61.
Morishita E Sekiya A Hayashi T Kadohira Y Maekawa M Yamazaki M Asakura H Nakao S Ohtake S 《International journal of hematology》2008,88(3):272-277
Previous studies have found markedly elevated serum concentrations of proinflammatory cytokines in patients with Graves’ disease
(GD). We investigated the role of macrophage colony-stimulating factor (M-CSF) in GD. We assayed concentrations of M-CSF in
sera from 32 patients with GD (25 untreated; 7 receiving thiamazole therapy). We also studied 32 age-matched healthy subjects
as controls. Relationships between serum M-CSF and both thyroid state and serum lipids were examined. Moreover, to examine
the effect of thyroid hormone alone on serum M-CSF, T3 was administered orally to normal subjects. Serum concentrations of
M-CSF in GD patients who were hyperthyroid were significantly increased compared with GD patients who were euthyroid (P < 0.05) and control subjects (P < 0.0001). Serum M-CSF concentrations correlated closely with T3 levels in patients (r = 0.51, P < 0.005). Serial measurement of five individual patients revealed that serum concentrations of M-CSF were significantly decreased
(P < 0.05), reaching normal control values upon attainment of euthyroidism. Furthermore, oral T3 administered to 15 volunteers
for 7 days produced significant increases in serum levels of M-CSF (P < 0.05). The close correlation between serum M-CSF and serum thyroid hormone levels suggests that high circulating levels
of thyroid hormones may directly or indirectly potentiate the production of M-CSF in patients with GD. 相似文献
62.
Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction 总被引:13,自引:0,他引:13
Sugano Y Anzai T Yoshikawa T Maekawa Y Kohno T Mahara K Naito K Ogawa S 《Cardiovascular research》2005,65(2):446-456
OBJECTIVE: In the early phase after transmural myocardial infarction (MI), the infarcted myocardium undergoes replacement by scar tissue, which is essential for preserving the structural integrity of the infarcted tissue. Transforming growth factor (TGF)-beta1, which is known as a fibrotic cytokine, plays a pivotal role in the reparative fibrosis after MI. It is reported that granulocyte colony-stimulating factor (G-CSF) can accelerate wound healing. The aim of our study was to investigate the effect of G-CSF on early ventricular expansion after MI. METHODS: MI was induced by ligation of the left coronary artery in male Wistar rats. G-CSF (20 microg/kg/day, MI-GCSF) or saline (MI-saline) was injected subcutaneously 3 h after MI and every 24 h thereafter for 7 days. Hemodynamic and echocardiographic studies were performed at 14 days. Expression of TGF-beta1 and procollagen type I and type III mRNA in both the infarcted and noninfarcted areas was studied by quantitative RT-PCR at 1, 3, 7, and 14 days after MI. Histological studies were performed at 7 days. RESULTS: MI-GCSF had higher LV max dP/dt, lower LV end-diastolic pressure, and smaller LV end-diastolic and end-systolic dimensions compared to MI-saline. Infarct size was not different between MI-GCSF and MI-saline. Expression of TGF-beta1 mRNA in the infarcted area at 3 days was significantly higher in MI-GCSF than in MI-saline. Expression of procollagen type I and type III mRNA in the infarcted area at 3 days was higher in MI-GCSF compared to MI-saline, and the peak mRNA levels were earlier in MI-GCSF. In the noninfarcted area, there was no difference in TGF-beta1 mRNA expression between MI-GCSF and MI-saline. Histologically, collagen accumulation in the infarcted area at 7 days was more prominent in MI-GCSF than in MI-saline. CONCLUSION: G-CSF treatment improves early post-infarct ventricular expansion through promotion of reparative collagen synthesis in the infarcted area, suggesting some beneficial effect of G-CSF on the infarct healing process. 相似文献
63.
Akihiko?Inoue Toru?Hifumi Yasuhiro?Kuroda Naoki?Nishimoto Kenya?Kawakita Susumu?Yamashita Yasutaka?Oda Kenji?Dohi Hitoshi?Kobata Eiichi?Suehiro Tsuyoshi?Maekawa 《Critical care (London, England)》2018,22(1):352
Background
The association between isolated admission heart rate (HR) and prognosis has been discussed, but not that between gross HR change and neurological outcome in patients with severe traumatic brain injury (TBI). In the acute phase of severe TBI, HR is influenced by several factors (e.g., pain, sympathetic activation, hypovolemia, fever, body temperature). Therefore, admission HR and gross HR change should be examined in patients with TBI treated with a well-designed protocol, such as was done in the Brain Hypothermia (B-HYPO) Study.Methods
This was a post hoc analysis of the B-HYPO Study, which was conducted as a prospective, multicenter, randomized controlled trial in patients with severe TBI receiving mild therapeutic hypothermia (MTH; 32.0?°C–34.0?°C) or fever control (35.5?°C–37.0?°C) in Japan. Patients with MTH were examined, and HR change (%HR) in the early MTH phase was calculated as follows: [admission HR – HR at day 1]/admission HR?×?100. Patients were divided into six groups, using admission HR (<?80, 80–99, ≤?100) and median of %HR; i.e., group (Admission HR <?80 and %HR ≥?18.6); group (Admission HR <?80 and %HR <?18.6); group (Admission HR 80–99 and %HR ≥?18.6); group (Admission HR 80–99 and %HR <?18.6); group (Admission HR ≥100 and %HR ≥?18.6); and group (Admission HR ≥100 and %HR <?18.6). The primary outcome was an adjusted predicted probability of unfavorable neurological outcome at 6 months after TBI according to Glasgow Outcome Scale score, which is a measure of functional recovery and defined as severe disability, persistent vegetative state, and death.Results
Overall, 79 patients with MTH (52.7% of the original trial) were examined; among these, unfavorable neurological outcomes were observed in 53.2%. Among all the groups, group (Admission HR ≥100 and %HR <?18.6) exhibited the highest proportion of unfavorable outcomes, and 82.3% of patients had an adjusted predicted probability of unfavorable outcomes, whereas those in group (Admission HR <?80 and %HR ≥?18.6) developed only 22.8% (p?=?0.04).Conclusions
Mild HR decrease during the early phase of targeted temperature management following tachycardia at admission can be associated with unfavorable neurological outcomes after severe TBI.64.
Kuroda J Kamitsuji Y Kimura S Ashihara E Kawata E Nakagawa Y Takeuichi M Murotani Y Yokota A Tanaka R Andreeff M Taniwaki M Maekawa T 《International journal of hematology》2008,87(5):507-515
Since a variety of cell intrinsic and extrinsic molecular abnormalities cooperatively promote tumor formation in multiple myeloma (MM), therapeutic approaches that concomitantly target more than one molecule are increasingly attractive. We herein demonstrate the anti-myeloma effect of a cephalotaxus alkaloid, homoharringtonine (HHT), an inhibitor of protein synthesis, through the induction of apoptosis. HHT significantly reduced Mcl-1, a crucial protein involved in myeloma cell survival, in all three myeloma cell lines examined, whereas certain BH3-only proteins, such as Bim, Bik, and Puma, remained unchanged following HHT treatment, and their expression levels depended on the cell type. HHT also reduced the levels of c-FLIP(L/S), activated caspase-8, and induced active truncated-Bid. Thus, HHT-induced apoptosis appears to be mediated via both intrinsic and extrinsic apoptosis pathways, and the resultant imbalance between BH3-only proteins and Mcl-1 may be pivotal for apoptosis by HHT. In addition, HHT treatment resulted in reduced levels of beta-catenin and XIAP proteins, which also contribute to disease progression and resistance to chemotherapy in MM. In combination, HHT enhanced the effects of melphalan, bortezomib, and ABT-737. These results suggest that HHT could constitute an attractive option for MM treatment though its ability to simultaneously target multiple tumor-promoting molecules. 相似文献
65.
66.
67.
68.
Fukuhara T Miyake T Maekawa I Kurosawa M Suzuki S Noto S Mori A Chiba K Toyoshima T Hirano T Morioka M Tsutsumi Y Okabe M Kakinoki Y 《International journal of hematology》2000,71(4):366-371
The treatment of patients with aggressive subclasses of myelodysplastic syndrome (MDS) remains a challenge. In an effort to improve the survival of patients with refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-t), or acute myelogenous leukemia transformed from MDS (MDS-AML), we conducted a small trial in which 28 such patients were treated with low-dose cytosine arabinoside (LDAraC) followed by administration of macrophage colony-stimulating factor (M-CSF). The overall rate of response to the treatment was 61%, including 39% with a complete response, which is higher than rates obtained in previous studies in which LDAraC alone was administered to patients with MDS. Median survival was 23.5 months in cases of RAEB, 16.7 months in cases of RAEB-t, and 19.7 months in cases of MDS-AML. The overall survival of the study group appeared to be prolonged in comparison with a historical control group of patients treated with LDAraC alone. It is suggested that M-CSF added to the administration of LDAraC plays an active role in the therapy. No therapy-related death occurred. Some unique actions of M-CSF were suggested in this trial. It is concluded that therapy with LDAraC + M-CSF is a useful treatment option for patients with aggressive subclasses of MDS and MDS-AML to provide better response and survival. 相似文献
69.
Protective effect of partially purified human urinary colony-stimulating factor on granulocytopenia after antitumor chemotherapy 总被引:3,自引:0,他引:3
K Motoyoshi F Takaku T Maekawa Y Miura K Kimura S Furusawa M Hattori T Nomura H Mizoguchi M Ogawa 《Experimental hematology》1986,14(11):1069-1075
We conducted a randomized crossover study comparing the hemopoietic effect of partially purified human urinary colony-stimulating factor (CSF-HU, an active drug) and human serum albumin (HSA, a control drug) in 24 patients with malignant lymphoma, solid tumors, or multiple myeloma who were receiving two consecutive courses of the same chemotherapeutic regimen. Patients received daily 2-4 X 10(6) units of CSF-HU or an equal amount of protein HSA for five days after the end of the courses of chemotherapy. Assignment to CSF-HU or HSA was determined by the envelope method. The average number of blood granulocytes of 24 cases on day 7 after chemotherapy was 2116 +/- 1649 in CSF-HU-infused courses, which was significantly higher than in HSA-infused courses (1520 +/- 1022) (p less than 0.05). The average time that patients had fewer than 2000 granulocytes/mm3 was 7.6 +/- 4.4 days in CSF-HU-infused courses and 10.3 +/- 5.0 days in HSA-infused courses (p less than 0.02). Fever greater than 38 degrees C was the most frequent side effect, occurring in 32% of the patients receiving CSF-HU infusions. A reduction in the neutropenic interval in CSF-HU-infused courses was observed in patients with fever, as well as in those without fever. Infusions of CSF-HU did not change the number of other hematological parameters, such as erythrocytes, platelets, monocytes, and lymphocytes. These results suggest that CSF-HU infusions may partially protect the patients from granulocytopenia after anticancer chemotherapy. 相似文献
70.
New Platelet Antigen, Siba , Involved in Platelet Transfusion Refractoriness in a Japanese Man 总被引:1,自引:0,他引:1
Mr. Hiroh Saji Director Etsuko Maruya Hiroshi Fujii Taira Maekawa Yuichi Akiyama Takao Matsuura and Takemitsu Hosoi 《Vox sanguinis》1989,56(4):283-287
Siba, a new platelet-specific alloantigen involved in a case of platelet transfusion refractoriness is reported. The IgG platelet alloantibody was detected in a multiply transfused patient of Japanese extraction (Sib), by the presence of HLA antibodies. After transfusion of HLA-compatible platelets, the patient suffered from refractoriness. Adsorption studies with pooled lymphocytes showed that the serum contained anti-platelet activity. Family studies indicate that Siba is inherited as an autosomal codominant trait and separate from HLA and Baka. As of this report, segregation from Zw(PlA) and Yuk (Pen) antigen systems have not yet been determined. The gene frequency of Siba in the Japanese population is estimated to be 0.136. 相似文献